| Dr Bret T Sobota, MD | |
|
500 University Dr, Hershey, PA 17033-2360 | |
| (717) 531-6822 | |
| (717) 531-4907 |
| Full Name | Dr Bret T Sobota |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 30 Years |
| Location | 500 University Dr, Hershey, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518051036 | NPI | - | NPPES |
| 560617 | Other | PA | HEALTH AMERICA |
| 867633 | Other | PA | MEDICARE GROUP # |
| 25-1716306 | Other | PA | MULTIPLAN/PHCS |
| 7064055 | Other | PA | AETNA NON-HMO |
| 1018454060001 | Medicaid | PA | |
| 1367953 | Other | PA | HIGHMARK BLUESHIELD |
| 25-1716306 | Other | PA | INTERGROUP |
| 25-1716306 | Other | PA | FIRST HEALTH |
| G920-0054 | Other | PA | CAREFIRST |
| 2163302 | Other | PA | MAMSI |
| 25-1716306 | Other | PA | GREATWEST HEALTHCARE |
| P00411722 | Other | PA | RAILROAD MEDICARE |
| 25-1716306 | Other | PA | DEVON |
| 25-1716306 | Other | PA | HEALTHNET/TRICARE |
| 1007307260034 | Other | PA | MEDICAID GROUP # |
| 120420405 | Other | PA | DEPT OF LABOR |
| MD062010L | Other | PA | PA LICENSE |
| 1547181 | Other | PA | GATEWAY |
| 25-1716306 | Other | PA | INFORMED |
| 25-1716306 | Other | PA | SOUTH CENTRAL PREFERRED |
| 3830436 | Other | PA | AETNA HMO |
| 50066685 | Other | PA | CAPITAL BLUECROSS |
| Facility Name | Location | Facility Type |
|---|---|---|
| Holy Spirit Hospital | Camp hill, PA | Hospital |
| St Joseph Medical Center | Reading, PA | Hospital |
| Upmc Pinnacle Hanover | Hanover, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Penn State Health Community Medical Group Llc | 8729351077 | 646 |
News Archive
Pancreatic cancer is the fourth most common cause of cancer related deaths in the United States with a five-year survival rate of less than 10 percent. Although it is defined by a small number of genetic alterations, efforts to pharmacologically target specific pathways have been unsuccessful.
Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has entered into a research and exclusive license agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize XMT-1107, a novel fumagillin analog, for the treatment of all indications, including cancer.
Foundation Medicine, a personalized cancer medicine company that aims to bring comprehensive cancer genome analysis into routine clinical care, today announced it has completed a $25 million Series A financing led by Third Rock Ventures.
The threat of bullying doesn't stop at the schoolyard gate nor does it end when the final bell signals the beginning of summer vacation, warns Dr. Jennifer Caudle of the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine. Dr. Caudle is a family physician who has lectured on the subject of bullying to thousands of schoolchildren, parents and educators across the country.
Obese drivers are far less likely to wear seatbelts than are drivers of normal weight, a new University at Buffalo study has found, a behavior that puts them at greater risk of severe injury or death during motor vehicle crashes.
› Verified 2 days ago
| Entity Name | The Milton S Hershey Medical Center Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710951744 PECOS PAC ID: 3870405483 Enrollment ID: O20040225000741 |
News Archive
Pancreatic cancer is the fourth most common cause of cancer related deaths in the United States with a five-year survival rate of less than 10 percent. Although it is defined by a small number of genetic alterations, efforts to pharmacologically target specific pathways have been unsuccessful.
Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has entered into a research and exclusive license agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize XMT-1107, a novel fumagillin analog, for the treatment of all indications, including cancer.
Foundation Medicine, a personalized cancer medicine company that aims to bring comprehensive cancer genome analysis into routine clinical care, today announced it has completed a $25 million Series A financing led by Third Rock Ventures.
The threat of bullying doesn't stop at the schoolyard gate nor does it end when the final bell signals the beginning of summer vacation, warns Dr. Jennifer Caudle of the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine. Dr. Caudle is a family physician who has lectured on the subject of bullying to thousands of schoolchildren, parents and educators across the country.
Obese drivers are far less likely to wear seatbelts than are drivers of normal weight, a new University at Buffalo study has found, a behavior that puts them at greater risk of severe injury or death during motor vehicle crashes.
› Verified 2 days ago
| Entity Name | Pinnacle Health Medical Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932143427 PECOS PAC ID: 7618960493 Enrollment ID: O20040407000180 |
News Archive
Pancreatic cancer is the fourth most common cause of cancer related deaths in the United States with a five-year survival rate of less than 10 percent. Although it is defined by a small number of genetic alterations, efforts to pharmacologically target specific pathways have been unsuccessful.
Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has entered into a research and exclusive license agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize XMT-1107, a novel fumagillin analog, for the treatment of all indications, including cancer.
Foundation Medicine, a personalized cancer medicine company that aims to bring comprehensive cancer genome analysis into routine clinical care, today announced it has completed a $25 million Series A financing led by Third Rock Ventures.
The threat of bullying doesn't stop at the schoolyard gate nor does it end when the final bell signals the beginning of summer vacation, warns Dr. Jennifer Caudle of the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine. Dr. Caudle is a family physician who has lectured on the subject of bullying to thousands of schoolchildren, parents and educators across the country.
Obese drivers are far less likely to wear seatbelts than are drivers of normal weight, a new University at Buffalo study has found, a behavior that puts them at greater risk of severe injury or death during motor vehicle crashes.
› Verified 2 days ago
| Entity Name | Penn State Health Community Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861988644 PECOS PAC ID: 8729351077 Enrollment ID: O20170907002279 |
News Archive
Pancreatic cancer is the fourth most common cause of cancer related deaths in the United States with a five-year survival rate of less than 10 percent. Although it is defined by a small number of genetic alterations, efforts to pharmacologically target specific pathways have been unsuccessful.
Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has entered into a research and exclusive license agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize XMT-1107, a novel fumagillin analog, for the treatment of all indications, including cancer.
Foundation Medicine, a personalized cancer medicine company that aims to bring comprehensive cancer genome analysis into routine clinical care, today announced it has completed a $25 million Series A financing led by Third Rock Ventures.
The threat of bullying doesn't stop at the schoolyard gate nor does it end when the final bell signals the beginning of summer vacation, warns Dr. Jennifer Caudle of the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine. Dr. Caudle is a family physician who has lectured on the subject of bullying to thousands of schoolchildren, parents and educators across the country.
Obese drivers are far less likely to wear seatbelts than are drivers of normal weight, a new University at Buffalo study has found, a behavior that puts them at greater risk of severe injury or death during motor vehicle crashes.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bret T Sobota, MD 500 University Dr Mc Ca410, Hershey, PA 17033-2360 Ph: (717) 531-5208 | Dr Bret T Sobota, MD 500 University Dr, Hershey, PA 17033-2360 Ph: (717) 531-6822 |
News Archive
Pancreatic cancer is the fourth most common cause of cancer related deaths in the United States with a five-year survival rate of less than 10 percent. Although it is defined by a small number of genetic alterations, efforts to pharmacologically target specific pathways have been unsuccessful.
Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has entered into a research and exclusive license agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize XMT-1107, a novel fumagillin analog, for the treatment of all indications, including cancer.
Foundation Medicine, a personalized cancer medicine company that aims to bring comprehensive cancer genome analysis into routine clinical care, today announced it has completed a $25 million Series A financing led by Third Rock Ventures.
The threat of bullying doesn't stop at the schoolyard gate nor does it end when the final bell signals the beginning of summer vacation, warns Dr. Jennifer Caudle of the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine. Dr. Caudle is a family physician who has lectured on the subject of bullying to thousands of schoolchildren, parents and educators across the country.
Obese drivers are far less likely to wear seatbelts than are drivers of normal weight, a new University at Buffalo study has found, a behavior that puts them at greater risk of severe injury or death during motor vehicle crashes.
› Verified 2 days ago
Neerav Goyal, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 717-531-8521 | |
Dr. Scott Walen, M.D., FRCSC Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 800-243-1455 Fax: 717-531-4907 | |
Dr. Jessyka G Lighthall, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 800-243-1455 | |
Dr. Mark E. Whitaker, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 717-531-6822 Fax: 717-531-4907 | |
Sohrab Sohrabi, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 800-243-1455 | |
Irina Chaikov, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 717-531-8521 | |
Heather Schopper, Otolaryngology Medicare: Medicare Enrolled Practice Location: 500 University Dr, Hershey, PA 17033 Phone: 800-243-1455 |